Reviva Pharmaceuticals Holdings Stock Performance
| RVPHW Stock | USD 0.05 0 4.65% |
The company holds a Beta of -0.63, which implies possible diversification benefits within a given portfolio. As returns on the market increase, returns on owning Reviva Pharmaceuticals are expected to decrease at a much lower rate. During the bear market, Reviva Pharmaceuticals is likely to outperform the market. At this point, Reviva Pharmaceuticals has a negative expected return of -0.66%. Please make sure to check Reviva Pharmaceuticals' potential upside and day median price , to decide if Reviva Pharmaceuticals performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
Very Weak
Weak | Strong |
Over the last 90 days Reviva Pharmaceuticals Holdings has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of inconsistent performance in the last few months, the Stock's technical indicators remain fairly stable which may send shares a bit higher in April 2025. The latest fuss may also be a sign of long-term up-swing for the venture sophisticated investors. ...more
1 | Reviva Pharmaceuticals Holdings, Inc. Sees Significant Decline in Short Interest | 01/14/2025 |
2 | Reviva to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference - Marketscreener.com | 02/04/2025 |
3 | Acquisition by Saxena Parag of 5300 shares of Reviva Pharmaceuticals at 3.78 subject to Rule 16b-3 | 03/07/2025 |
| Begin Period Cash Flow | 18.5 M |
Reviva |
Reviva Pharmaceuticals Relative Risk vs. Return Landscape
If you would invest 17.00 in Reviva Pharmaceuticals Holdings on December 28, 2024 and sell it today you would lose (11.60) from holding Reviva Pharmaceuticals Holdings or give up 68.24% of portfolio value over 90 days. Reviva Pharmaceuticals Holdings is currently producing negative expected returns and takes up 16.274% volatility of returns over 90 trading days. Put another way, most equities are less risky on the basis of their return distribution than Reviva, and majority of traded equity instruments are likely to generate higher returns over the next 90 trading days. Expected Return |
| Risk |
Reviva Pharmaceuticals Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Reviva Pharmaceuticals' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Reviva Pharmaceuticals Holdings, and traders can use it to determine the average amount a Reviva Pharmaceuticals' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.0405
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | RVPHW |
Estimated Market Risk
| 16.27 actual daily | 96 96% of assets are less volatile |
Expected Return
| -0.66 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.04 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Reviva Pharmaceuticals is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Reviva Pharmaceuticals by adding Reviva Pharmaceuticals to a well-diversified portfolio.
Reviva Pharmaceuticals Fundamentals Growth
Reviva Stock prices reflect investors' perceptions of the future prospects and financial health of Reviva Pharmaceuticals, and Reviva Pharmaceuticals fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Reviva Stock performance.
| Return On Equity | -17.95 | ||||
| Return On Asset | -3.28 | ||||
| EBITDA | (39.5 T) | ||||
| Net Income | (39.26 M) | ||||
| Cash And Equivalents | 353.26 K | ||||
| Cash Per Share | 0.02 X | ||||
| Total Debt | 17.98 M | ||||
| Current Ratio | 0.03 X | ||||
| Book Value Per Share | (0.30) X | ||||
| Cash Flow From Operations | (28.32 M) | ||||
| Market Capitalization | 85.81 M | ||||
| Total Asset | 23.7 M | ||||
| Retained Earnings | (134.35 M) | ||||
| Working Capital | 6.53 M | ||||
About Reviva Pharmaceuticals Performance
Evaluating Reviva Pharmaceuticals' performance through its fundamental ratios, provides valuable insights into its operational efficiency and profitability. For instance, if Reviva Pharmaceuticals has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Reviva Pharmaceuticals has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | -1.9 M | -1.8 M | |
| Return On Capital Employed | -7 M | -6.6 M | |
| Return On Assets | -1.9 M | -1.8 M | |
| Return On Equity | -7.9 M | -7.5 M |
Things to note about Reviva Pharmaceuticals performance evaluation
Checking the ongoing alerts about Reviva Pharmaceuticals for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Reviva Pharmaceuticals help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Reviva Pharmaceuticals generated a negative expected return over the last 90 days | |
| Reviva Pharmaceuticals has high historical volatility and very poor performance | |
| Reviva Pharmaceuticals has some characteristics of a very speculative penny stock | |
| Reviva Pharmaceuticals has high likelihood to experience some financial distress in the next 2 years | |
| Reviva Pharmaceuticals Holdings has accumulated 17.98 M in total debt. Reviva Pharmaceuticals has a current ratio of 0.03, indicating that it has a negative working capital and may not be able to pay financial obligations in time and when they become due. Note, when we think about Reviva Pharmaceuticals' use of debt, we should always consider it together with its cash and equity. | |
| Net Loss for the year was (39.26 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Reviva Pharmaceuticals Holdings has accumulated about 353.26 K in cash with (28.32 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.02. | |
| Reviva Pharmaceuticals has a poor financial position based on the latest SEC disclosures | |
| Latest headline from MacroaxisInsider: Acquisition by Saxena Parag of 5300 shares of Reviva Pharmaceuticals at 3.78 subject to Rule 16b-3 |
- Analyzing Reviva Pharmaceuticals' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Reviva Pharmaceuticals' stock is overvalued or undervalued compared to its peers.
- Examining Reviva Pharmaceuticals' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Reviva Pharmaceuticals' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Reviva Pharmaceuticals' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Reviva Pharmaceuticals' stock. These opinions can provide insight into Reviva Pharmaceuticals' potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Reviva Stock Analysis
When running Reviva Pharmaceuticals' price analysis, check to measure Reviva Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Reviva Pharmaceuticals is operating at the current time. Most of Reviva Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Reviva Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Reviva Pharmaceuticals' price. Additionally, you may evaluate how the addition of Reviva Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.